An extensive study launched to test formerly reported associations of candidate gene markers (including TGFB1, but not TGFBR1) for impact on early or late side effects of radiotherapy in breast and prostate cancer did not prove a statistically significant risk for any of the markers tested [38]. The gene discussed is TGFBR1; the disease is prostate cancer.